Abstract
Bispecific therapeutic antibodies are active in relapsed B-cell malignancies by dual engagement of a tumor cell surface antigen and CD3 on T-cells,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
